Literature DB >> 7693688

Structure-function relationship of the insulin-like growth factor-I receptor tyrosine kinase.

M Grønborg1, B S Wulff, J S Rasmussen, T Kjeldsen, S Gammeltoft.   

Abstract

Insulin-like growth factor I (IGF-I) and insulin receptors are structurally similar with ligand-stimulated tyrosine kinase activity in their cytoplasmic domains. The function of the insulin receptor tyrosine kinase in signal transduction has been studied extensively in contrast to the IGF-I receptor tyrosine kinase. In the present study we have analyzed the regulatory function of the IGF-I receptor tyrosine kinase and carboxyl-terminal domains in mitogenic signaling by overexpression of mutant IGF-I receptors in mouse NIH-3T3 fibroblasts. A mutant IGF-I receptor, in which 3 tyrosines (Tyr1131, Tyr1135, and Tyr1136) analogous to the three major autophosphorylation sites in the insulin receptor kinase were replaced by phenylalanines, was devoid of kinase activity in vivo and in vitro and inactive with respect to IGF-I internalization and stimulation of thymidine incorporation. Another mutant IGF-I receptor, which lacks the 49 carboxyl-terminal amino acids (residues 1289-1337) of the beta-subunit, was fully active. Our data suggest that the structure-function relationship of the IGF-I receptor tyrosine kinase activation and signal transduction is similar to that of the insulin receptor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7693688

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  Growth factors regulate phototransduction in retinal rods by modulating cyclic nucleotide-gated channels through dephosphorylation of a specific tyrosine residue.

Authors:  A Savchenko; T W Kraft; E Molokanova; R H Kramer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

2.  Expression and distribution of IGF-1 receptors containing a beta-subunit variant (betagc) in developing neurons.

Authors:  F Mascotti; A Cáceres; K H Pfenninger; S Quiroga
Journal:  J Neurosci       Date:  1997-02-15       Impact factor: 6.167

3.  A model to explain specific cellular communications and cellular harmony:- a hypothesis of coupled cells and interactive coupling molecules.

Authors:  Cyril J Craven
Journal:  Theor Biol Med Model       Date:  2014-09-14       Impact factor: 2.432

4.  Tumor necrosis factor (TNF)-α-induced repression of GKAP42 protein levels through cGMP-dependent kinase (cGK)-Iα causes insulin resistance in 3T3-L1 adipocytes.

Authors:  Yasutoshi Ando; Yusuke Shinozawa; Yumi Iijima; Bu-Chin Yu; Meri Sone; Yuko Ooi; Yusuke Watanaka; Kazuhiro Chida; Fumihiko Hakuno; Shin-Ichiro Takahashi
Journal:  J Biol Chem       Date:  2015-01-13       Impact factor: 5.157

5.  The differential effects of pp120 (Ceacam 1) on the mitogenic action of insulin and insulin-like growth factor 1 are regulated by the nonconserved tyrosine 1316 in the insulin receptor.

Authors:  P Soni; M Lakkis; M N Poy; M A Fernström; S M Najjar
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

6.  Interaction in vitro of the product of the c-Crk-II proto-oncogene with the insulin-like growth factor I receptor.

Authors:  A P Koval; V A Blakesley; C T Roberts; Y Zick; D Leroith
Journal:  Biochem J       Date:  1998-03-01       Impact factor: 3.857

Review 7.  Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy.

Authors:  Jennifer Wu; Evan Yu
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

Review 8.  Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?

Authors:  Terry J Smith
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

9.  Prolactin enhances insulin-like growth factor I receptor phosphorylation by decreasing its association with the tyrosine phosphatase SHP-2 in MCF-7 breast cancer cells.

Authors:  Kristopher C Carver; Timothy M Piazza; Linda A Schuler
Journal:  J Biol Chem       Date:  2010-01-15       Impact factor: 5.157

10.  Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma.

Authors:  Paul Haluska; Frank Worden; David Olmos; Donghua Yin; David Schteingart; Gretchen N Batzel; M Luisa Paccagnella; Johann S de Bono; Antonio Gualberto; Gary D Hammer
Journal:  Cancer Chemother Pharmacol       Date:  2009-08-02       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.